A First-in-Class Pan-Lysyl Oxidase Inhibitor Impairs Stromal Remodeling and Enhances Gemcitabine Response and Survival in Pancreatic Cancer

Using small-molecule drug-design approaches, the authors generated and validated PXS-5505, a first-in-class highly selective and potent pan-lysyl oxidase inhibitor.